At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 24, 2026 at 07:45 ET
Ocugen announced positive 12-month Phase 2 data for OCU410, its gene therapy for geographic atrophy (GA) secondary to dry AMD, showing a statistically significant 31% reduction in lesion growth versus control (p < 0.05) and strong safety with no serious adverse events. The company plans to initiate a Phase 3 trial in Q3 2026, positioning OCU410 as a potential one-time treatment addressing a major unmet need in a growing patient population.
- OCU410 showed 31% reduction in GA lesion growth at 12 months (p < 0.05) in the optimal dose group
- No OCU410-related serious adverse events or adverse events of special interest reported
- 27% slower rate of ellipsoid zone (EZ) loss, indicating structural preservation of photoreceptors
- 55% of treated patients achieved ≥30% lesion size reduction vs. control
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access